---
figid: PMC10295864__biomedicines-11-01610-g001
pmcid: PMC10295864
image_filename: PMC10295864__biomedicines-11-01610-g001.jpg
figure_link: /pmc/articles/PMC10295864/figure/F1/
number: Figure 1
figure_title: Effector mechanisms of therapeutic mAbs in cancer therapy.
caption: 'Effector mechanisms of therapeutic mAbs in cancer therapy. (A) Signaling
  pathway blocking. (B) Antibody-dependent cellular cytotoxicity. (C) Complement-dependent
  cytotoxicity. (D) Antibody-dependent cellular phagocytosis. AKT: Protein kinase
  B, ERK: extracellular signal-regulated kinase, C1q: complement component 1q, MAC:
  Membrane attack complex, FcγRIII: Fc-gamma receptor III, FcγRI: Fc-gamma receptor
  I. Image created in BioRender (www.biorender.com, accessed on 20 January 2023)'
article_title: Mechanisms of Action and Limitations of Monoclonal Antibodies and Single
  Chain Fragment Variable (scFv) in the Treatment of Cancer
citation: Cynthia Rodríguez-Nava, et al. Biomedicines. 2023 Jun;11(6).
year: '2023'
pub_date: 2023-6-
epub_date: 2023-6-01
doi: 10.3390/biomedicines11061610
journal_title: Biomedicines
journa_nlm_ta: Biomedicines
publisher_name: MDPI
keywords:
- cancer
- monoclonal antibodies
- scFv
- treatment
- mechanism of action
---
